Your browser doesn't support javascript.
loading
Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives.
Svärd, A; Roos Ljungberg, K; Brink, M; Martinsson, K; Sjöwall, C; Rantapää Dahlqvist, S; Kastbom, A.
Affiliation
  • Svärd A; Center for Clinical Research Dalarna, Uppsala University, Uppsala, Sweden.
  • Roos Ljungberg K; Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Brink M; Center for Clinical Research Dalarna, Uppsala University, Uppsala, Sweden.
  • Martinsson K; Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Sjöwall C; Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden.
  • Rantapää Dahlqvist S; Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Kastbom A; Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Clin Exp Immunol ; 199(2): 143-149, 2020 02.
Article in En | MEDLINE | ID: mdl-31605388
ABSTRACT
The aim of this study was to evaluate secretory antibodies to citrullinated proteins (ACPA) in plasma and immunoglobulin (Ig)A ACPA in saliva from patients with rheumatoid arthritis (RA) and their unaffected first-degree relatives (FDRs). Patients with RA (n = 194) and first-degree relatives unaffected by RA (n = 191) were recruited for analysis of secretory antibodies to second-generation cyclic citrullinated peptides (anti-CCP) in plasma. From a subpopulation (25 RA patients, 21 first-degree relatives and 11 controls), saliva samples were obtained for IgA anti-CCP analysis. The presence of secretory ACPA was compared between subject categories, and related to genetic and environmental risk factors. Secretory ACPA occurred in 37 (19%) plasma samples from patients with RA, but only in two (1%) of FDRs. IgA ACPA in saliva was found in three of 25 (12%) patients with RA, but not in any of the 21 FDRs (< 5%). No significant associations were seen between the presence of secretory ACPA and SE or smoking, either among RA patients or among FDRs. Despite occurring in 19% of RA plasma, secretory ACPA was rare in both saliva and plasma among FDRs, even among those positive for conventional ACPA of non-mucosal origin. Longitudinal studies are warranted to determine whether circulating secretory ACPA occurs before or in parallel with the development of clinical arthritis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides, Cyclic / Arthritis, Rheumatoid / Saliva / Salivary Proteins and Peptides / Autoantibodies / Immunoglobulin A / Family Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2020 Document type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides, Cyclic / Arthritis, Rheumatoid / Saliva / Salivary Proteins and Peptides / Autoantibodies / Immunoglobulin A / Family Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2020 Document type: Article Affiliation country: Sweden